Biome Grow Inc. (CSE:BIO) is a Canadian cannabis company with operations mainly concentrated in Atlantic Canada.   The company wholly owns five subsidiaries, including: The Back Home Medical Cannabis Corporation, a company incorporated under the laws of the Province of Newfoundland and Labrador and in the late stages of applying for a license under the Cannabis Act; Great Lakes Cannabis, an Ontario company also in the late stages of applying for a license; Highland Grow Inc., a licensed producer in Nova Scotia; Red Sands Craft Cannabis Co., a Prince Edward Island company set up to provide extraction services; and Weed Virtual Retail Inc., an Ontario company in the business of operating a new virtual reality technology and education platform.  In addition to these domestic cultivation and distribution assets, Biome also has five retail licenses in Newfoundland with stores opening this year as well as a significant MOU to be supplied a large quantity of CBD from a third-party supplier.  The company hopes to leverage the CBD business both at home and abroad by producing and exporting a range of CBD infused products starting late 2019.

BioVaxys Technology Corp. is a British Columbia-registered biopharmaceuticals company based in Ontario, Canada that is developing BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© 'neoantigen' tumor cell construct platform for treating refractive late stage ovarian cancer. BioVaxys is also exploring vaccines for additional cancers and infectious diseases based on its HapTenix©platform through academic and other collaborations.

BaM is an operations-focused cannabis company with active retail operations Illinois and California and pending retail operations in Illinois and New Jersey.

We work daily to increase our market share through delighting customers while also continuing to hone our operational efficiencies to drive profits. We are primarily guided by the metric of return on investment. Currently, we believe the most significant return on investment projects in front of us are successful retail cannabis store launches in Illinois and New Jersey, which augment our existing retail footprint. We also believe that our team’s core operational skillsets will create significant future shareholder value as the cannabis industry matures.

Bright Minds is a pre-clinical biosciences company with a portfolio of compounds designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. Bright Minds is focused on developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious neuropsychiatry drugs into the clinic. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin. Bright Minds was selected to participate in two National Institutes of Health (“NIH”) Programs. These NIH collaborations are evaluating Bright Minds serotonin agonists for therapeutic potential in pain and in epilepsy.